Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799006 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00799006 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 27 participants.
The verdict
NCT00799006, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics following a single oral dose.
Interventions
- DRUG Placebo
- DRUG PF-04620110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00799006
The ClinicalTrials.gov registry entry for NCT00799006 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00799006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00799006 about?
NCT00799006 is a clinical study titled "A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers". PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics following a single oral dose.
What is the current status of trial NCT00799006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2008-11. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00799006?
The interventions under investigation include: Placebo (DRUG), PF-04620110 (DRUG).
Who is sponsoring clinical trial NCT00799006?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.